Hypomethylating agents (HMAs) are frontline therapy for Myelodysplasia, but their efficacy is limited. Here, the authors show that depleting the dual E3-ligase TOPORS synergizes with HMAs by enhancing DNA damage in leukemia cells, improving survival in mouse models without preventing healthy hematopoiesis.
- Peter Truong
- Sylvie Shen
- John E. Pimanda
